Federal Register of Legislation - Australian Government

Primary content

PB 68 of 2009 Determinations/Health as made
This Determination amends the National Health Act 1953 - Determination under paragraph 98C(1)(b) - conditions (No. PB 119 of 2008) to provide conditions for payments in respect of supply of pharmaceutical benefits by approved pharmacists and medical practitioners.
Administered by: Health
Registered 10 Jul 2009
Tabling HistoryDate
Tabled HR11-Aug-2009
Tabled Senate11-Aug-2009
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 68 of 2009

Amendment determination under paragraph 98C(1)(b) of the National Health Act 1953

I, LINDA JACKSON, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under paragraph 98C(1)(b) of the National Health Act 1953.

 

Dated 6 July 2009

 

 

 

 

 

LINDA JACKSON

Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing


Amendment determination — conditions

1              Commencement                                                        

                This instrument commences on 1 August 2009.

2              Amendment of PB 119 of 2008

                Schedule 1 amends PB 119 of 2008.



Schedule 1            Amendments

 

[1]     Schedule 1, after item dealing with Mycophenolic Acid with

          Water — Purified BP

insert in the columns in the order indicated:

Voriconazole with Water — Purified BP

Powder for oral suspension 40 mg per mL, 70 mL

[2]     Schedule 4, after item dealing with Bimatoprost

insert in the columns in the order indicated:

Bimatoprost with timolol

Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL

[3]     Schedule 4, item dealing with Glucose Indicator—Blood

omit from the column headed “Form”:

 

Electrode strips, 100 (TrueSense)

[4]     Schedule 4, after item dealing with Hypromellose in the form Eye drops 5 mg per mL, 15 mL

insert in the column headed “Form”:

 

Oral gel 20 mg per g, 100 g

[5]     Schedule 4, after item dealing with Ondansetron

insert in the columns in the order indicated:

Oxybutynin

Transdermal patches 36 mg, 8

[6]     Schedule 4, after item dealing with Risperidone

insert in the columns in the order indicated:

Rivaroxaban

Tablet 10 mg, 15

 

Tablet 10 mg, 30

[7]     Schedule 4, after item dealing with Varenicline

insert in the columns in the order indicated:

Voriconazole

Powder for oral suspension 40 mg per mL, 70 mL